Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Sales (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Return on Sales for 2 consecutive years, with 2291.44% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 229096.0% to 2291.44% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.99% through Dec 2025, up 304.0% year-over-year, with the annual reading at 1.91% for FY2025, 296.0% up from the prior year.
  • Return on Sales hit 2291.44% in Q4 2025 for Silence Therapeutics, up from 131.81% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 2291.44% in Q4 2025 to a low of 200.92% in Q1 2025.